Precision BioSciences (DTIL) Projected to Post Earnings on Monday

Precision BioSciences (NASDAQ:DTIL) is projected to release its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect Precision BioSciences to post earnings of ($0.31) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Monday, November 3, 2025 at 7:00 AM ET.

Precision BioSciences (NASDAQ:DTIL) last issued its earnings results on Thursday, August 7th. The company reported ($2.13) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($2.04). Precision BioSciences had a negative return on equity of 176.47% and a negative net margin of 6,205.79%.The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $6.27 million. On average, analysts expect Precision BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Precision BioSciences Price Performance

Shares of NASDAQ DTIL opened at $6.72 on Monday. Precision BioSciences has a 1-year low of $3.61 and a 1-year high of $9.14. The business has a 50-day moving average of $5.38 and a 200-day moving average of $5.03. The company has a debt-to-equity ratio of 0.66, a current ratio of 5.18 and a quick ratio of 5.18. The company has a market capitalization of $79.23 million, a price-to-earnings ratio of -0.76 and a beta of 1.72.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Precision BioSciences in a research report on Saturday. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $47.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Corient Private Wealth LLC purchased a new position in Precision BioSciences in the second quarter valued at about $425,000. Geode Capital Management LLC boosted its holdings in Precision BioSciences by 5.5% in the second quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock valued at $326,000 after purchasing an additional 4,025 shares during the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in Precision BioSciences in the second quarter valued at about $260,000. Hedge funds and other institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.